Bio-Path’s (BPTH) “Buy” Rating Reaffirmed at Roth Mkm

Roth Mkm reissued their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a research note published on Thursday, Benzinga reports. Roth Mkm currently has a $40.00 price objective on the stock.

Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Tuesday. They set a sell rating for the company.

Bio-Path Price Performance

Shares of NASDAQ BPTH opened at $4.20 on Thursday. The company has a 50 day simple moving average of $5.50 and a 200 day simple moving average of $8.53. The firm has a market cap of $2.86 million, a PE ratio of -0.10 and a beta of 0.35. Bio-Path has a 1 year low of $2.70 and a 1 year high of $44.80.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same quarter in the prior year, the business posted ($10.60) earnings per share. As a group, research analysts anticipate that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Bio-Path by 77.5% during the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after purchasing an additional 117,914 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Bio-Path during the 3rd quarter worth approximately $77,000. Renaissance Technologies LLC acquired a new stake in shares of Bio-Path during the 2nd quarter worth approximately $70,000. Citadel Advisors LLC acquired a new stake in shares of Bio-Path during the 3rd quarter worth approximately $35,000. Finally, Virtu Financial LLC acquired a new stake in shares of Bio-Path during the 1st quarter worth approximately $38,000. Institutional investors own 5.74% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.